Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term

Alnylam Pharmaceuticals (ALNY), a biopharmaceutical company specializing in RNAi therapeutics with several approved drugs, is highlighted as a strong momentum stock. Despite holding a Zacks Rank #3 (Hold), ALNY exhibits a Momentum Style Score of A, supported by 10 analysts raising fiscal 2025 earnings estimates by $2.06 to $3.66 per share in the last 60 days, and an average earnings surprise of +348.4%. This indicates significant positive earnings momentum and analyst confidence for the company.

Analysis

Alnylam Pharmaceuticals (ALNY) presents a compelling case for momentum, supported by strong underlying fundamental signals despite a neutral Zacks #3 (Hold) rating. The primary driver is a significant upward shift in earnings expectations for fiscal 2025, with the consensus estimate increasing by $2.06 to $3.66 per share following upward revisions by 10 analysts in the last 60 days. This powerful earnings momentum, reflected in a top-tier 'A' Momentum Style Score, is further contextualized by the company's track record of delivering an average earnings surprise of +348.4%, suggesting a history of conservative Street estimates. While recent share price movement has been modest, with a gain of only 0.7% over the past four weeks, the positive analyst revisions may be linked to fundamental catalysts such as the recent label expansion for its drug Amvuttra. The combination of a high VGM score of 'B' and exceptional earnings momentum indicates a strengthening outlook that may not be fully reflected in the current stock price or its neutral rating.

Key Decisions for Investors

• Given the significant upward revision in the fiscal 2025 consensus earnings estimate to $3.66 per share, investors should view the strengthening analyst sentiment as a primary bullish indicator that may supersede the neutral Zacks #3 'Hold' rating.
• Momentum-oriented investors could interpret the disconnect between the strong 'A' momentum score and the modest 0.7% share price gain over the last four weeks as a potential entry point before the market fully digests the improved earnings outlook.
• It is crucial to monitor for any change in the Zacks Rank from its current 'Hold' status, as an upgrade would provide further confirmation of the positive underlying fundamentals highlighted by the high momentum and VGM scores.